



PACULit

# MAY NEWSLETTER

## STUDY 1: THE IMPACT OF THE 2024 INTRAVENOUS FLUID SHORTAGE ON EMERGENCY DEPARTMENT LENGTH OF STAY AND 72-HOUR RETURN RATE

**Authors:** Stenson BA, Shaw DL, MacDougall G, Kolikof J, Gaudet C, Grossestreuer A, Sanchez LD, Chiu DT

**Background:** An abrupt nationwide IV fluid shortage in 2024 led to rationing protocols in emergency departments (EDs).

**Study Objective:** Evaluate the impact of IV fluid rationing on ED metrics.

**Study Design:** Retrospective cohort study comparing pre- and post-shortage periods.

**Intervention:** IV fluid rationing implemented post-shortage.

### Results:

- Reduced IV Fluid Utilization: Decreased from 24% pre-shortage to 20% post-shortage.
- Shorter ED Length of Stay: Median ED LOS decreased from 7.8 hours to 7.1 hours ( $p < 0.001$ ) for discharged patients with gastrointestinal symptoms.
- No Significant Change in 72-Hour Return Rates: No difference observed in the 72-hour return rate ( $p = 0.156$ ).

## STUDY 2: NIRSEVIMAB PROPHYLAXIS ON PEDIATRIC INTENSIVE CARE HOSPITALIZATION FOR SEVERE ACUTE BRONCHIOLITIS

**Authors:** Sarah Touati, Alexandre Debs, Luc Morin, Laure Jule, Caroline Claude, Pierre Tissieres

**Background:** Severe acute bronchiolitis is a leading cause of PICU admissions. Nirsevimab is an anti-RSV monoclonal antibody.

**Study Objective:** Assess the impact of Nirsevimab prophylaxis on PICU admissions and costs.

**Study Design:** Retrospective cohort study over six winter seasons.

**Intervention:** Universal neonatal Nirsevimab prophylaxis (2023–2024).

### Results:

- 9.1% Reduction in PICU Admissions: Admission rate decreased from 17.6% to 8.5% ( $p < 0.001$ ).
- 25% Reduction in PICU Length of Stay: Decreased from 4.4 days to 3.3 days ( $p = 0.02$ ).
- Cost Savings: Annual cost reduced by €89,061 without altering cost-effectiveness ratios.

## STUDY 3: RESCUE KETAMINE FOR PREHOSPITAL STATUS EPILEPTICUS

**Authors:** Leah Lawrence

**Background:** Ketamine is used as a rescue therapy for benzodiazepine-resistant status epilepticus.

**Study Objective:** Evaluate ketamine's effectiveness as a rescue intervention for prehospital SE.

**Study Design:** Seven-year observational cohort of adults treated for SE after midazolam failure.

**Intervention:** 100 mg ketamine administered after midazolam failure.

### Results:

- Rapid seizure termination in 98.2% of patients following 100 mg ketamine administration.
- No recurrence during prehospital care and only one recurrence after hospital transfer.

## STUDY 4: PROTHROMBIN COMPLEX CONCENTRATE (PCC) IN MILD TRAUMATIC BRAIN INJURY

**Authors:** Douillet, Delphine; Tazarourte, Karim; Dehours, Emilie; Brice, Christian; et al.

**Background:** Rapid VKA reversal is crucial for TBI patients to prevent ICH.

**Study Objective:** Compare immediate PCC vs. CT-guided reversal in TBI patients.

**Study Design:** Randomized controlled trial across 21 French EDs.

**Intervention:** Immediate 25 IU/kg PCC versus CT-guided reversal.

**Results:** Non-Significant Reduction in ICH Rates: 6.1% ICH in the PCC group vs. 12.1% in the control group (OR 0.47, 95% CI 0.14–1.44;  $P = 0.215$ ).

## STUDY 5: HEMODYNAMIC EFFECTS OF ADJUNCT ARGININE VASOPRESSIN IN SEPTIC SHOCK

**Authors:** Douillet, Delphine; Tazarourte, Karim; Dehours, Emilie; Brice, Christian; et al.

**Background:** Identifying factors predicting AVP response can optimize septic shock management.

**Study Objective:** Determine factors predicting AVP responsiveness in septic shock.

**Study Design:** Multicenter observational registry study across 11 ICUs.

**Intervention:** Adjunctive AVP with norepinephrine for septic shock.

### Results:

- Hemodynamic Response: 79% of patients responded to AVP, with obesity and higher lactate levels decreasing response, while a higher norepinephrine dose ( $\geq 0.30$   $\mu\text{g/kg/min}$ ) improved response.
- Shock Duration: Prolonged with higher BMI, increased norepinephrine dose, and longer norepinephrine use; higher pH reduced duration.
- Rebound Hypotension: Occurred in 9% of patients after AVP cessation, but using AVP for over 24 hours significantly lowered this risk.

Subscribe to  
**PACULit Newsletter**  
for up-to-date information



Watch  
the full  
video on  
**YouTube:**

